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Abbreviations 
CHO, carbohydrate 
ConA, Concanavalin A 
EU, ELISA units 
GAS, group A streptococcus 
GAS-PS, GAS polysaccharide 
GNL, Galantus Nivalis Lectin 
HA, hemagglutinin 
HSA, human serum albumin. 
i.m., intramuscular 
i.p., intraperitoneal 
Man, mannose 
RT, room temperature 
sc., subcutaneous 
vol, volume 
wt, weight 
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Introduction 
Carbohydrate-based vaccines 
Glycoconjugate vaccines, in which a cell surface carbohydrate from a micro-
organism is covalently attached to an appropriate carrier protein, have been 
proved to be one of the most effective means to generate protective immune 
responses to prevent a wide range of diseases. The technology appears to be 
generic and applicable to many pathogen agents, as long as antibodies against 
surface carbohydrates help protect against infection. 
The cell surfaces of bacteria, parasites and viruses exhibit oligosaccharides that 
are often distinct from those of their hosts. Carbohydrates are virulence factors 
commonly used by pathogens to establish an infection and escape the host 
immune response. The polysaccharide capsules of bacteria prevent 
complement activation (Roitt 1997) and inhibit phagocytosis. Carbohydrates 
form protective shields over conserved viral protein epitopes (Baghian et al. 
2000; Scanlan et al. 2002; Sanders et al. 2002; Mori et al. 2003; Han et al. 2004; 
Barrientos, Gronenborn 2005; Goffard et al. 2005; Helle et al. 2006), serve for 
interaction with host cell surface receptors leading to enhancement of viral 
spread (Pohlmann et al. 2001; Alvarez et al. 2002; Halary et al. 2002; Klimstra et 
al. 2003; Lozach et al. 2005; Davis et al. 2006) or induction of 
immunosuppressive response (Shan et al. 2007). Thus, carbohydrate antigens 
represent an attractive target for vaccine development. 
Pneumococcal capsular polysaccharide appeared the first carbohydrate antigen 
of a pathogen to be investigated for vaccine application. Immunogenic and 
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protective properties of pneumoccocal polysaccharide had been investigated 
starting from as early as 1920s. In 1980s two formulations of anti-pneumococcal 
vaccine have been introduced containing capsular polysaccharide derived from 
14 and 23 pneumonia serotypes, respectively. However, the vaccine was poorly 
immunogenic in infants under the ages of two, elderly and immunocompromised 
persons (Vliegenthart 2006). The same limitation was revealed for 
meningococcal polysaccharide vaccines (Broker et al. 2009).  
Carbohydrates themselves do not represent ideal vaccines due to the fact that, 
with a fewer exceptions, they cannot not be presented in the context of MHC-
antigen complex to the T-helper cells and therefore are poor immunogens (Avci, 
Kasper 2009). However, carbohydrate conjugation to carrier proteins results in 
the induction of T-cell-dependent arm of the adaptive immunity. The age of 
glycoconjugate vaccines started in 1931, when Avery and Goedel discovered 
that covalent attachment of carbohydrates to a suitable protein induced an 
enhanced immunogenicity compared to the polysaccharides as such (Avery, 
Goedel 1931). Carbohydrate-protein conjugates therefore are capable of 
eliciting a long-lasting response to vaccination and are effective in adults and 
young children. 
Polysaccharides have been successfully conjugated to a variety of proteins, 
such as tetanus toxoid, diphtheria toxoid and its non-toxic mutant CRM197, the 
outer membrane complex from Neisseria meningitidis (Giannini et al. 1984; 
Verez-Bencomo et al. 2004; Jones 2005; Pace 2009). Using these protein 
carriers effective conjugate vaccines against Haemophilus influenza type b, 
meningococcus of the serogroups A, C, W, Y, and pneumococcus (13-valent 
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formulation) have been developed (Jones 2005; Lucas et al. 2005). Novel 
findings proposed short peptides and proteins containing specific CD4+ T cell 
epitopes as potential candidates with improved carrier properties for the future 
applications (Falugi et al. 2001; Liakatos, Kunz 2007). 
Isolated bacterial carbohydrates for conventional vaccines 
Vaccines prepared with bacterial polysaccharides have been widely used 
against a host of diseases for several decades (Goldblatt 1998). The 
carbohydrate antigens for those vaccines were traditionally isolated from 
biological sources. A potent set of analytical tools as NMR, mass spectrometry 
and others have helped to investigate the structure of bacterial carbohydrate 
antigens. Native polysaccharides are either homopolymers or made up of 
between two and six repeating sugar units, the chemical nature of which defines 
the serotype of the organism. For example, there are 91 different types of 
polysaccharides associated with pneumococci, 13 polysaccharides of 
meningococci, and 9 polysaccharides of group B streptococci (Paoletti and 
Madoff 2002; Sabharwal et al. 2006; Pollard et al. 2009). 
Protective immunity against encapsulated bacteria has been correlated with 
anti-polysaccharide antibodies. Usually immune response is serotype-specific, 
and multivalent formulations containing several types of polysaccharides are 
preferred for vaccination e.g. 14- and 23-valent pneumococcus vaccine 
(Vliegenthart 2006), unless the only type of polysaccharide is ascribed for the 
circulating virulent strains as in case of group A Streptococcus (Cunningham 
2000). Commercially available vaccines based on purified capsular 
polysaccharides or glycoconjugates include those against Neisseria 
 6
meningitidis, Streptococcus pneumoniae, Haemophilus influenza type b and 
Salmonella typhi (Ada, Isaacs 2003). 
Synthetic oligosaccharides as new targets for vaccine development 
In contrast to conventional polysaccharide isolation, chemical synthesis provides 
access to pure, homogeneous oligosaccharides of well-defined structure that 
contain single reactive groups for covalent conjugation. Additionally, in some 
cases synthetic oligosaccharides were found to have better immunogenic 
properties than native polysaccharides (Pozsgay et al. 1999). Design of 
synthetic oligosaccharides is usually based on the core antigenic determinants 
of long polysaccharide chains and may help to evaluate how particular structural 
features e.g. length, conformation, or non-reducing end residue, influence 
carbohydrate immunogenicity. Conjugate vaccines containing synthetic 
oligosaccharides have generated a protective immune response for a growing 
number of infectious diseases including Streptococcus pneumonia type 3, 6A, 
6B and 14, Shigella dysenteriae type 1 and Haemophilus influenzae type b 
(Chong et al. 1997; Benaissa-Trouw et al. 2001; Jansen et al. 2001; Verez-
Bencomo et al. 2004; Pozsgay et al. 2007; Safari et al. 2008). Until recently, the 
major obstacle to the development of synthetic carbohydrate vaccines were the 
challenges associated with the chemical synthesis of oligosaccharides. 
Automated oligosaccharide synthesis promises now ready access to synthetic 
antigens and tools such as glycan microarrays to assess an immune response 
and to map antibody epitopes. Synthetic antigens formed the basis for tumor 
vaccines candidates as well as Bacillus anthracis, Plasmodium falciparum and 
Leishmania conjugate vaccines (Schofield et al. 2002; Liu et al. 2006; Ragupathi 
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et al. 2006; Liakatos, Kunz 2007; Galonic, Gin 2007; Kamena et al. 2008; 
Robbins et al. 2009). 
Focus of the doctorate study 
This PhD thesis discusses the rationale for design and use of synthetic 
oligosaccharides for the development of glycoconjugate vaccines and the role of 
physicochemical methods in the characterization of these vaccines. The study 
concerns two infectious diseases that represent a serious problem for the 
national healthcare programs: human immunodeficiency virus (HIV) and Group 
A Streptococcus (GAS) infections. Both pathogens possess distinctive 
carbohydrate structures that have been described as suitable targets for the 
vaccine design. 
The Group A Streptococcus cell membrane polysaccharide (GAS-PS) is an 
attractive vaccine antigen candidate based on its conserved, constant 
expression pattern and the ability to confer immunoprotection in a relevant 
mouse model. Analysis of the immunogenic response within at-risk populations 
suggests an inverse correlation between high anti-GAS-PS antibody titres and 
GAS infection cases. Recent studies show that a chemically synthesized core 
polysaccharide-based antigen may represent an antigenic structural determinant 
of the large polysaccharide. Based on GAS-PS structural analysis, the study 
evaluates the potential to exploit a synthetic design approach to GAS vaccine 
development and compares the efficiency of synthetic antigens with the long 
isolated GAS polysaccharide. Synthetic GAS-PS structural analogues were 
specifically designed and generated to explore the impact of antigen length and 
terminal residue composition. 
 8
For the HIV-1 glycoantigens, the dense glycan shield on the surface of the 
envelope protein gp120 was chosen as a target. This shield masks conserved 
protein epitopes and facilitates virus spread via binding to glycan receptors on 
susceptible host cells. The broadly neutralizing monoclonal antibody 2G12 binds 
a cluster of high-mannose oligosaccharides on the gp120 subunit of HIV-1 Env 
protein. This oligomannose epitope has been a subject to the synthetic vaccine 
development. The cluster nature of the 2G12 epitope suggested that multivalent 
antigen presentation was important to develop a carbohydrate based vaccine 
candidate. Hereafter I will describe the development of neoglycoconjugates 
displaying clustered HIV-1 related oligomannose carbohydrates and their 
immunogenic properties. 
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Chapter 1 
Preparation, characterization and immunogenicity of HIV-1 
related high-mannose oligosaccharides-CRM197 
glycoconjugates 
Introduction 
Worldwide human immunodeficiency virus (HIV) pandemic involves 
approximately 33 millions of people with 2.7 millions of new infections and 2 
millions of deaths each year (WHO, 2007). It is generally believed that an 
effective prophylactic weapon against HIV-1 could be a vaccine capable of 
eliciting both neutralizing antibodies and T-cell responses. However, numerous 
defense mechanisms help HIV-1 to evade host immune attacks directed against 
HIV envelope (Env) neutralization epitopes by means of frequent mutations, 
structural occlusions achieved by protein complex formation and heavy 
glycosylation (Kwong et al. 2002; Pantophlet, Burton 2006; Wei et al. 2003). The 
latter leads to formation of so-called “glycan shield” that masks conserved 
protein epitopes (Burton et al.  2005; Calarese et al. 2003). This shield provides 
to the virus an additional source of antigen heterogeneity due to the numerous 
glycoforms in which proteins can exist and, being produced by the host 
glycosylation machinery, is expected to induce immune tolerance. Nevertheless, 
a unique carbohydrate epitope mapped by the human broadly neutralizing 
monoclonal antibody 2G12 was discovered on the surface of Env gp120 giving 
to HIV glycans potential to be considered as candidates for an anti HIV-1 
vaccine (Burton et al. 2004). 
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The neutralizing carbohydrate epitope of gp120 consists of a cluster of terminal 
α-D-Man-(1,2)-α-D-Man residues (Manα1,2-Man) on the D1 and D3 arms of 
Man9GlcNAc2 residues (Calarese  et al. 2005; Scanlan  et al. 2002). An 
extended antibody binding surface is formed by a unique heavy chain variable 
domain-swapped configuration which favors the possibility of multiple 
interactions with mannose surface (Calarese et al. 2003). Man4, Man6 and Man9 
derivatives of natural Man9GlcNAc2 oligosaccharide (Fig. 1) were proposed as 
possible “building blocks” of a future glycoconjugate vaccine because they 
possess Manα1,2-Man units essential for 2G12 recognition and have been 
proved to interact with 2G12 in binding and inhibition assays (Adams et al. 2004; 
Calarese et al. 2005; Lee et al. 2004; Wang et al. 2004). 
 
Figure 1. Structures of oligomannoses. 
 
The cluster nature of the 2G12 epitope suggests the importance of multivalent 
presentation of oligomannoses in developing glycoconjugate molecules as 
possible candidate vaccines. Synthetic high-mannose clusters of 2-, 4- and 
higher valence, compared to monovalent sugars, showed enhanced binding to 
2G12 and up to 110 times lower IC50 when used as inhibitors of the interaction 
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between antibody and gp120 (Krauss et al. 2007; Wang J. et al. 2007; Wang et 
al. 2008). Two types of clustering scaffold have been investigated so far: in one 
case high mannoses were randomly oriented by a flexible linker around a 
galactose core (Wang et al. 2004; Ni et al. 2006); in a different study a semirigid 
cyclic peptide scaffold served to position the carbohydrate moieties at the 
correct distance as defined by the crystal structure of gp120 (Krauss et al. 2007; 
Wang J. et al. 2007). The latter strategy seemed to provide a better mimic of the 
native epitope, but the sterical constraints of the model led to incorporation of a 
lower number of carbohydrate chains (Joyce et al. 2008). In summary, up to now 
three HIV-related glycoconjugates have been used for in vivo studies: the 
monovalent Man4 conjugated to BSA (Astronomo et al. 2008), the bivalent 
Man9GlcNAc2 on the cyclic peptide scaffold conjugated to Neisseria 
meningitides outer membrane protein complex (OMPC) (Joyce et al. 2008), and 
the galactose-based tetravalent Man9GlcNAc2-cluster conjugated to Tetanus 
toxoid T-helper peptide (Ni et al. 2006). None of them elicited “2G12-like” 
response that cross-reacted with HIV Env proteins. 
During my thesis I have investigated polyamidoamine (PAMAM) dendrons as 
possible scaffolds to make clusters with HIV-1 related high-mannose 
oligosaccharides (Fig. 2). PAMAM dendrons appeared attractive due to their 
potential low immunogenicity (Chabre, Roy 2008; Boas et al. 2006) and built-in 
surface functionalities which provide multiple sites for sugar incorporation. The 
high-mannose oligosaccharide clusters have been coupled to CRM197, a non-
toxic mutant of diphtheria toxin already extensively used as carrier for 
glycoconjugate vaccines in humans (Broker et al. 2009; Giannini et al. 1984; 
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Jackson et al. 2009). Formulated with the human acceptable adjuvant MF59 
(Burke et al. 2009; Galli et al. 2009; Seubert et al. 2008), the glycoconjugates 
were tested in rabbits and mice. I report here preparation, structural 
characterization, antigenic and immunogenic properties of these oligomannose-
PAMAM-CRM197 conjugates. 
 
Figure 2. Synthesis of PAMAM-oligosaccharide clusters. 
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Results 
Oligomannose cluster synthesis and characterization 
High-mannose oligosaccharides equipped with a six-carbon amino linker at the 
reducing end were first converted into the corresponding succinimidyl adipate 
esters and then reacted with PAMAM4 or PAMAM8 (Fig. 2). The glycodendrons 
were purified by C4 hydrophobic interaction cartridge where the excess of 
unreacted oligosaccharides eluted in the flow through. Fractions containing the 
fully derivatized PAMAM were identified by ESI Q-TOF MS. 
Glyco-PAMAM4 dendrons were analyzed by direct infusion of the sample into Q-
TOF system, glyco-PAMAM8 dendrons were analyzed by UPLC paired 
(coupled) to Q-TOF. The general pattern of the ESI-MS spectra showed 
molecular ion peaks related to the fully derivatized PAMAMs as major species 
and a slight fragmentation of molecules due to the loss of Man units starting 
from the molecular ion peak, as better evidenced in the deconvoluted spectra. 
The ESI-MS analysis of the Man4PAMAM8 UPLC peak (Fig. 3) showed multiple 
molecular ions corresponding to the Man4PAMAM8 molecule (8760.14 Da) 
bearing different charges, the most abundant of which was the 5+ molecular ion, 
although 3+, 4+ and 6+ ions were present as well. 
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Figure 3. LC-MS profile of Man4PAMAM8. 
 
Man4PAMAM4 (4346.05 Da) was characterized by the presence of the 3+ and 
the 4+ molecular ions as most intense peaks (Fig. 4). 
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Figure 4. LC-MS profile of Man4PAMAM4. 
 
Prominent ions in the spectrum of Man9PAMAM4 (7587.11 Da) were the 4+ 
charged (Fig. 5). The presence of a molecular ion with a mass of 4157.13 Da 
was attributed to the reaction of activated Man9 with a PAMAM4 minor 
contamination, where an ethylenediamine unit (60 Da) had been lost. This 
contamination is most likely a side product from incomplete reaction during the 
synthesis of PAMAM dendrimer as reported by others (Schwartz et al. 1995). 
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Figure 5. LC-MS profile of Man9PAMAM4. 
 
The ESI spectrum of Man9PAMAM8 (15242.25 Da) (Fig. 6) presented the 6+ ion 
as prominent peaks and two minor contaminations. The first was attributed to 
the PAMAM8 derivatized with solely 2 Man9 units. The second corresponded to 
the PAMAM8 conjugated to 6 Man9 moieties and presenting a bridging between 
two ethylendiamines through an adipate molecule, very likely due to a 
contamination of activated Man9. However, we deemed the desired 
Man9PAMAM8 cluster the most abundant product 
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Figure 6. LC-MS profile of Man9PAMAM8. 
 
Immunochemical characterization of oligomannose antigens 
In order to determine the relative ability of the different oligomannose systems to 
bind 2G12, I performed competitive experiments using surface plasmon 
resonance (SPR). HIV protein gp140 UG37 was immobilized on a Biacore CM5 
chip, and 2G12 with and without inhibitors was injected over it. Initial screening 
of monovalent oligomannoses showed inferior inhibitory capacity of Man6 as 
compared to Man4 and Man9. In fact, 1.2 mM Man4 and 0.54 mM Man9 inhibited 
gp140-2G12 interaction by 84.0% and 68.8%, respectively, while 0.81 mM Man6 
showed only 12.4%. I therefore concentrated attention on Man4 and Man9 
antigens and explored if clustering influences the binding ability to 2G12. 
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SPR inhibition assay evidenced lower IC50 values for PAMAM4 and PAMAM8 
clusters, as compared to their respective monovalent oligosaccharides (Fig. 7). 
An example of the inhibition assay sensorgrams is presented on Figure 8. 
IC50 of Man4PAMAM4 and Man9PAMAM4 clusters were 13 and 11 times lower 
than IC50 of Man4 and Man9, respectively; moreover IC50 of Man4PAMAM8 and 
Man9PAMAM8 clusters were 2 and 2.6 times lower than IC50 of Man4PAMAM4 
and Man9PAMAM4, respectively. The absolute IC50 values were comparable for 
both Man4 and Man9 clusters. Thus multivalent presentation of oligomannose 
increased their avidity to 2G12, and the smaller D1-armed Man4 competed for 
2G12 at the same level as D1D3-armed Man9. 
 
 
Figure 7. Biacore inhibition of 2G12-gp140 interaction by monovalent and clustered 
oligomannoses. Inhibition was calculated as difference in maximal binding. 
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Figure 8. Sensorgrams of the surface plasmon resonance inhibition assay on the example of 
Man9PAMAM4. Legend of each figure indicates inhibitor concentrations. 
 
Synthesis of CRM197 glycoconjugates 
A well-established way to improve poor immunogenicity of carbohydrate 
antigens is the conjugation to a protein carrier which provides T cell epitopes. 
Therefore, high-mannose oligosaccharides have been coupled, plain or 
PAMAM-clustered, to the lysine residues of CRM197.  Using disuccinimidyl 
adipate linker chemistry (Fig. 2) I have synthesized a panel of glycoconjugates 
that have been characterized by carbohydrate/protein ratio (wt/wt) and SDS-
PAGE. The glycosylation degree ranged from 39.0 to 58.4% (Table I). 
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Gel line 
(Fig. 8) 
Antigen 
Mw of the 
hapten 
portion (Da) 
Average molar ratio 
of CHO unitsa or 
clustersb to protein 
CHO/Protein 
% wt/wt 
Expected 
glycoconjugate 
average Mw 
(Da) 
1 Man9-CRM197 1659 16
a 43.8 84544 
2 Man4PAMAM4-CRM197 4356 10
b 43.6 101560 
3 Man9PAMAM4-CRM197 7600 6
b 58.4 103600 
4 Man4PAMAM8-CRM197 8770 4
b 39.0 93080 
5 Man9PAMAM8-CRM197 15258 2
b 44.1 88516 
Table I. Chemical characteristics of high-mannose glycoconjugates. 
 
In SDS-Page (Fig. 9) the glycoconjugates migrated with diffuse bands which 
cover a region consistent with the expected increase of Mw as compared to 
CRM197 and suggesting certain heterogeneity of the glycoconjugate molecules 
due to the multiple conjugation sites on CRM197 represented by 39 lysine 
residues in its structure (Bardotti et al. 2008). 
Additional characterization verified neoglycoconjugate recognition by 2G12 in 
ELISA assay (Fig. 10), in which equivalent amounts of glycoproteins were 
captured to microplate wells and then detected with 2G12 and GNL. The latter 
has specificity for α1-3/α1-6 mannoses and served as a positive control (Hester, 
Wright 1996; Krishnamoorthy et al. 2009). No 2G12 recognition was observed 
for Man6PAMAM4-CRM197 neither in ELISA, nor in western-blot. 
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Figure 9. CRM197 glycoconjugates with synthetic oligosaccharides and clusters analyzed by 
coomassie-stained SDS-PAGE in 4-12% Bis-Tris gel. Line numbers indicate Man9-CRM197 (1), 
Man4PAMAM4-CRM197 (2), Man9PAMAM4-CRM197 (3), Man4PAMAM8-CRM197 (4) and 
Man9PAMAM8-CRM197 (5). 
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Figure 10. Binding of oligomannose glycoconjugates to 2G12 and GNL lectin. Oligomannose 
glycoconjugates were coated on ELISA microplates at 100 ng/well. CRM197 was used as 
negative control. Each value is the mean±SD of four replicates. 
 
Glycoconjugates immunogenicity in rabbits and mice 
Initially we tested the immunogenicity of Man4- and Man9-PAMAM 
glycoconjugates compared to Man9-CRM197. Man4/Man9-PAMAM4 and 
Man4/Man9-PAMAM8 glycoconjugates were tested at 20 and 5 µg carbohydrate 
dose, respectively, in group of 2-4 rabbits. In all cases the antigens were 
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formulated with MF59, an oil-in-water buffered emulsion of 5% squalene, 0.5% 
Tween 80 and 0.5% Span 85 (Seubert et al. 2008). 
First, the antibody response was assessed by means of ELISA with Man9 
conjugated to HSA via squarate linker as coating reagent. Since different carrier 
and coupling chemistry was used, this ELISA revealed only oligomannose-
specific antibodies. As seen in Fig. 11 a,b,c all glycoconjugate antigens induced 
Man9-specific IgG titer, and in particular it was manifested that Man9-
glycoantigens, clustered or plain, elicited a stronger antibody response in 
comparison to Man4 antigens. No significant carbohydrate-specific IgM titers 
were detected (data not shown). 
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Figure 11. Detection of anti-Man9 antibodies for single rabbit (a, b, c) and pooled mice (b) 
antisera. Sera are matched with corresponding immunization antigens. Coating antigen has 
been synthesized with different conjugation chemistry in order to detect antibodies specific only 
for synthetic oligomannose part. 
 
Following the main goal of this study, the cross-reactivity of the rabbit sera 
against HIV-1 gp120 proteins was examined then. Several clade B gp120 
proteins were coated onto ELISA microplates and tested against pools of rabbit 
post immunization sera. None of the gp120 proteins showed cross-reactivity with 
antiserum panel, meanwhile as expected 2G12 and GNL did recognize 
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everyone (Fig. 12). 
 
Figure 12. Binding of pooled animal antisera to HIV-1 gp120 glycoproteins. Rabbit antisera: 
PBS-MF59 (+), Man9-CRM197 (□), Man4PAMAM4-CRM197 (<), Man9PAMAM4-CRM197 (>), 
Man4PAMAM8-CRM197 (◊) and Man9PAMAM8-CRM197 (*); mice antisera: preimmune (■), 
Man4PAMAM4-CRM197 (▲), Man9PAMAM4-CRM197 (●); GNL (○) and 2G12 (▼). GNL and 2G12 
have 2 and 10 µg/mL at first graph point, respectively; two-fold dilution scheme was applied. 
 
In order to collect data with a different animal model Man4PAMAM4-CRM197 and 
Man9PAMAM4-CRM197 were additionally tested in mice. Anti-Man9 antibodies 
were clearly elicited by the Man9 conjugate, while the response of 
Man4PAMAM4-CRM197 was weak (Fig. 11 d). Also in this case, when the 
antisera were tested against HIV-1 gp120, no cross reaction was observed (Fig. 
12). 
Anti-carrier antibody response 
The presence of anti-CRM197 antibodies in antiserum pools of rabbit and mice 
immunized with the different conjugates was examined, and it turned out that in 
all cases anti-carrier antibodies have been induced. Interestingly, in rabbit 
PAMAM-based conjugates seemed to induce a lower anti-carrier response as 
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compared to Man9-CRM197 which could be explained considering a certain 
shielding of relevant T- or B-cell epitopes of CRM197 by the glycodendron 
haptens (Fig. 13). 
 
Figure 13. Binding of pooled rabbit antisera to CRM197 glycoproteins. 
 
Discussion 
HIV is characterized by a densely glycosylated surface, which enhances the 
effectiveness of immune escape and is implicated in viral dissemination 
(Pohlmann et al. 2001; Shan et al. 2007). Human broadly neutralizing antibody 
2G12 and mannose-binding lectin cyanovirin-N were found to recognize high-
mannose oligosaccharides on the surface of HIV-1 gp120, and both 
demonstrated anti-HIV activity at nanomolar level (Bewley et al. 2001; Binley et 
al. 2004). Moreover, both 2G12 or cyanovirin-N have shown so far no 
autoimmune property, probably due to their strict specificity to dense 
oligomannose surfaces that have not been observed among human 
glycoproteins (Scanlan et al. 2002; Scanlan et al. 2007). This suggested that 
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high-mannose oligosaccharides are feasible targets for a vaccine aiming at 
eliciting “2G12”-like antibodies. Up to now various synthetic approaches have 
been applied to prepare clusters with the aim of mimicking the 2G12 epitope 
(Astronomo et al. 2008; Joyce et al. 2008; Ni et al. 2006), however, none of the 
obtained molecules reported gp120 cross-reactive immune response virtually 
due to initial low antigen affinity to 2G12. The affinity increase that can be 
achieved by multivalent presentation of carbohydrate ligands prompted us to 
explore PAMAM dendrons that offer high coupling valence and are low-
immunogenic per se (Chabre, Roy 2008; Boas et al. 2006). Utilization of such 
scaffolds could provide more control in spatial presentation of sugars than 
conjugation to Lys residues of carrier protein does, allowing a better emulation 
of the dense arrangement of oligomannoses on the gp120 glycan. In a recent 
study nine- and 27-valent oligomannose dendrons showed similar affinity and 
inhibition capacity in binding 2G12 to gp120 (Wang  et al. 2008), suggesting that 
rising cluster valence above nine moieties would not necessarily lead to further 
increase in the 2G12 affinity. 
In my thesis I report the first in vivo study with glycoconjugates containing four- 
and eight-valent high-mannose oligosaccharide dendrons. Obtained 
glycoconjugates consisted of the HIV-1 related carbohydrate antigens clustered 
onto the PAMAM dendrons and subsequently conjugated to CRM197, which is 
well known for its excellent properties as carrier for bacterial oligo- and 
polysaccharides and is widely used in licensed glycoconjugate vaccines 
(Bardotti et al. 2008; Broker et al. 2009; Mawas et al. 2004; Safari et al. 2008; 
Torosantucci et al. 2005). The antigens were formulated with the potent MF59 
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adjuvant which was shown to be effective in boosting both cellular and humoral 
immune response and being of common use for seasonal flu vaccination (Burke 
et al. 2009; Galli et al. 2009; Seubert et al. 2008). The combination of mentioned 
above factors was designed to confer to the glycoantigens improved 
immunogenic features. 
Oligomannoses for the development of our glycoantigens were chosen on the 
basis of biochemical, biophysical and crystallographic evidences available in the 
literature (Adams et al. 2004; Calarese et al. 2005; Calarese et al. 2003; Pashov 
et al. 2005; Sanders et al. 2002; Wang et al. 2008). Man4, Man6 and Man9 
candidates possessed terminal Manα1,2-Man units that were shown to be 
essential for 2G12 recognition being involved into binding in the antibody 
combining site (Calarese et al. 2005; Scanlan et al. 2002). Although it was 
expected that all three oligosaccharide candidates would demonstrate 2G12 
reactivity, Man6 antigen showed low potency as inhibitor compared to Man4 and 
Man9 oligosaccharides in SPR studies; moreover Man6PAMAM4-CRM197 did not 
demonstrate 2G12 binding in ELISA assay (Fig. 10). This may indicate that 
trisaccharide α-D-Man-(1,2)-α-D-Man-(1,2)-α-D-Man, present in both Man4 and 
Man9, is required for the affinity interaction. This observation is in line with the 
structural requirements of ligand binding for high-mannose-specific lectin 
cyanovirin-N (Bewley et al. 2001). 2G12 recognition of Man6 observed in the 
glycoarray studies indicates that this oligosaccharide benefits from dense 
multivalent display on the surface of microarray slide (Adams et al. 2004). 
Nevertheless, its structural features might be not sufficient to provide enough 
2G12 affinity in case of a lower density carbohydrate presentation. 
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Having this information at disposal, I focused only on Man4 and Man9 antigens. 
The preparation of high-mannose glycodendrons was based on the activation of 
the amino groups present in the oligosaccharide linkers with an excess of 
disuccinimidyl adipate, followed by the reaction of activated oligosaccharides 
with t-Boc-protected PAMAM (Yi et al. 1998). The effect of oligosaccharide 
multivalent presentation was evidenced by the enhancement of glycodendron 
capacity to inhibit 2G12-gp140 interaction (Fig. 7). After hydrolysis of the t-Boc 
group and activation of the amino function again with disuccinimidyl adipate, the 
clusters with four and eight oligomannose antennae were conjugated to CRM197. 
As a result I was able to synthesize glycoconjugates with 39-58% carbohydrate 
content, which is significantly higher than previous studies reporting a 15-19% 
range (elaborated from Astronomo et al. 2008; Joyce et al. 2008; Ni et al. 2006). 
Glycodendron conjugation to CRM197 did not seem to effect their conformation 
that was evidenced by maintenance of 2G12 recognition (Fig. 10). 
Immunization of rabbits and mice with MF59-formulated CRM197 
glycoconjugates of Man4 and Man9 antigens induced specific anti-Man9 
antibodies (Fig. 11). In all cases Man9-conjugates induced stronger response as 
compared to the Man4-conjugates, which can be easily explained considering 
the structural differences between Man4 and Man9  However, neither the four- 
nor the eight-valent flexible PAMAM dendron antigens induced gp120 cross-
reactive antibodies (Fig. 12), indicating that the presentation of oligomannose 
sugars was not sufficient to mimic the native carbohydrate epitopes. Previous 
studies conducted with glycoconjugates prepared from high-mannose 
oligosaccharides clustered onto scaffolds and then linked to diverse carriers, 
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such as BSA, OMPC or Tetanus toxoid T-helper peptide, have also failed to 
induce antibodies cross reactive with HIV-1 gp120 (Astronomo et al. 2008; 
Joyce et al. 2008; Ni et al. 2006). 
In the present work the different model based on the use of PAMAM dendrons 
as a way to display the HIV-1 related oligomannoses in a clustered form on the 
surface of CRM197 confirms the significant difficulties in the identification of a 
suitable carbohydrate-based anti-HIV vaccine candidate. The failure of high-
mannose-PAMAM-CRM197 conjugates to provide antibodies with affinity for 
gp120 could be explained with inappropriate spacing of oligomannose antennae 
in the synthesized clusters, too much flexibility introduced by the presence of 
two subsequent six-carbon spacer chains between the oligomannoses and the 
PAMAM core, or too wide separation among the cluster molecules on the carrier 
protein surface. Those issues should be definitively addressed in the future work 
for a synthetic anti-HIV vaccine. 
Recently reported data on the rabbit “2G12”-like serum response to 
immunization with Man8-reach mutant yeast cells gives a hint that the 
oligomannose density exposure is likely to be one of the dominating factors for 
designing HIV glycoantigens (Luallen et al. 2008; Luallen et al. 2009; Luallen et 
al. 2009 a). This outcome, which might be due to the abundant high-mannose 
glycosylation of yeast proteins comprising approximately 100% of protein weight 
(elaborated from ref. Luallen et al. 2009 and Luallen et al. 2009 a), suggests that  
finding the right density and exhibition of oligomannose surface could be the key 
for the search of best mimics of the native 2G12 epitope. 
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Chapter 2 
Rational design and evaluation of a synthetic carbohydrate-
based Group A Streptococcus vaccine candidate 
Introduction 
Group A Streptococcus (GAS) infections represent a significant healthcare 
concern throughout the world. GAS is responsible for a broad spectrum of 
diseases ranging from asymptomatic colonization, uncomplicated pharyngeal 
and skin infections to life-threatening invasive illnesses including sepsis, 
necrotizing fasciitis and toxic shock syndrome (Mitchell 2003). Epidemiology 
reveals correlations between bacterial strains responsible for GAS pharyngitis, a 
frequent childhood illness, and invasive streptococcal disease in adults 
(Haukness et al. 2002; Linder et al. 2005). Pharyngitis may lead to delayed 
sequela as rheumatic fever. In developing countries rheumatic fever remains 
endemic and causes hundreds of thousands of deaths every year (WHO 1992). 
Currently, no vaccine to prevent GAS infections exists although GAS has been 
on the WHO priority prevention list for decades. 
The diversity of GAS strains is the major challenge for the development of an 
anti-GAS vaccine. GAS bacteria contain a surface polysaccharide consisting of 
repeating [→3)α-L-Rhap(1→2)[β-D-GlcpNAc(1→3)]α-L-Rhap(1-]n units (Fig. 1). 
These long polysaccharide chains adopt a helical conformation where the 
rhamnoses form the helix core and the immunodominant N-acetylglucosamine 
residues are exposed on the periphery (Pitner et al. 2000; Johnson et al. 2002). 
The GAS polysaccharide (GAS-PS) is conserved and constantly expressed in 
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the vast majority of M+ GAS strain serotypes (Cunningham et al. 2000; 
Lancefield et al. 1933; Mc, Lancefield et al. 1955). The conserved nature of 
GAS-PS renders a potentially attractive conjugate vaccine. Purified GAS-
polysaccharide has been conjugated to tetanus toxoid carrier and elicited a 
protective immune response in a challenge model in mice (Sabharwal et al. 
2006). Serum anti-GAS-PS antibodies confer protection against GAS throat 
colonization and promote bacterial phagocytosis (Sabharwal et al. 2006; 
Salvadori et al. 1995). 
 
Figure 1. Structures of the repeating unit of the cell-wall polysaccharide of GAS. 
 
Efforts to determine the antibody-binding epitope of GAS-PS revealed a core 
antigenic determinant – a hexamer structure of two repeating units (Michon et al. 
2005). The human anti-GAS humoral is believed to recognize hexasaccharide 
(Michon et al. 2005). To date no evidence that a minimal GAS-PS core antigen 
determinant can elicit an immunoprotective response has been obtained. 
Up to now synthetic approaches applied to the development of carbohydrate 
vaccines has been evaluated in a very limited set of infection disease areas but, 
nevertheless, has shown its efficacy in the generation of a protective response 
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(Benaissa-Trouw et al. 2001; Chong et al. 1997; Jansen et al. 2001; Pozsgay et 
al. 2007; Robbins et al. 2009; Safari et al. 2008; Verez-Bencomo et al. 2004). 
Compared to the conventional polysaccharide isolation, the synthetic approach 
has an advantage of generating pure, homogeneous oligosaccharides of well-
defined structure, rationally planned to contain immunodominant saccharide 
composition and single-site reactive groups for covalent conjugation. Present 
study directly compares in vivo efficacy of CRM197 glycoconjugate of the native 
GAS-PS material versus that of the synthetic oligosaccharides designed to 
evaluate optimal oligosaccharide length and terminal molecule residues, as both 
parameters may influence carbohydrate immunogenicity (Benaissa-Trouw et al. 
2001; Jansen et al. 2001; Michon et al. 2005; Ragupathi et al. 2006; Safari et al. 
2008). Purified, native GAS-PS antigen (Fig. 1) and synthetic oligosaccharide 
structures 1-4 (Fig. 2) were coupled to CRM197 and tested in a relevant mouse 
model. 
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Figure 2. Structures of the synthetic oligosaccharides 1-4 designed for present work. 
 
Results 
GAS-PS isolation and purification 
Native GAS-PS was extracted from GAS SF370 M1 strain. Final GAS-PS 
preparation was characterized with <0.3% of DNA and <0.005% hyaluronic acid. 
MicroBCA assay detected 2-3% protein contamination; however, this value was 
confirmed neither by Bradford method, nor silver stain SDS-PAGE. This 
suggests that the MicroBCA detection was likely influenced by reducing groups 
of GAS-PS (Waffenschmidt, Jaenicke 1987; Franco-Fraguas et al. 2003). As 
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determined by multiple laser light scattering (MALLS), the average molecular 
weight of GAS-PS was 8.9 ± 1.0 kDa which corresponded to 18 repeating units; 
dn/dc value was 0.168 mL/g. 
Purified GAS-PS was additionally characterized by 1H NMR analysis. The 1H 
NMR spectrum was consistent with the published structure (Johnson, Pinto 
2002) (Fig. 3). It was possible to detect the so-called variant GAS 
polysaccharide, representing a polyrhamnose [→3)α-L-Rhap(1→2)α-L-Rhap(1-
]n without branching GlcNAc residues. In certain cases this variant carbohydrate 
substitutes typical GAS-PS in the bacteria cell wall after passage in mice (Mc, 
Lancefield 1955; Michon et al. 2005). In the 1H-NMR spectrum the signal of 
poly-rhamnose H1RhaB was shifted in comparison to conventional GAS CHO 
H1RhaB, while both variant and conventional H1RhaA signals were merged (Fig. 3). 
Integration of the variant H1RhaB and the merged H1RhaA peaks allowed us to 
calculate a molar ratio between poly-rhamnose and GlcNAc-containing species 
of GAS-PS: % polyrhamnose = [H1RhaBVAR/(H1RhaA+ H1RhaAVAR)] x 100. 
Polyrhamnose content for purified GAS-PS lots was <10% for typical 
polysaccharide preparations. 
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Figure 3. Expansion of the region of the 1H NMR spectrum of purified GAS cell wall 
polysaccharide. Assigned are the peaks crucial for the determination of residual polyrhamnose 
content. 
 
Generation and characterization of glycoconjugates 
A well-established way to improve poor immunogenicity of carbohydrate 
antigens is through conjugation to a protein carrier which provides T-cell 
epitopes. Therefore, the carbohydrate structures were coupled to lysine residues 
of CRM197, a non-toxic mutant of diphtheria toxin already extensively used as a 
carrier for glycoconjugate vaccines in humans (Broker et al. 2009; Giannini et al. 
1984; Jackson et al. 2009). Depending on whether the native or the synthetic 
saccharide was used, the conjugation of carbohydrate haptens to the lysines of 
the carrier protein was accomplished by two approaches (Fig. 4). In the case of 
synthetic oligosaccharides the amino groups on the linker were derivatized with 
disuccinimidyl adipate and subsequently coupled to CRM197. Native GAS-PS 
was instead conjugated to CRM197 via direct reductive amination. 
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Figure 4. Conjugation of GAS carbohydrates to CRM197. 
 
The conjugates were characterized by SDS/PAGE, carbohydrate/protein ratio, 
free saccharide, size exclusion HPLC, and MALDI-TOF mass spectrometry. In 
Fig. 5 the SDS-PAGE profile of different GAS conjugates provides evidence that 
glycosylation with the synthetic oligosaccharides produced conjugates with a 
more homogeneous pattern as compared to CRM197-GAS-PS, which had a 
significant polydispertion in the molecular size due to the larger carbohydrate 
hapten. 
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Figure 5. CRM197 glycoconjugates analyzed by coomassie-stained SDS-PAGE in 7% Tris-
Acetate gel. The glycoconjugates migrate with diffuse bands which cover a region consistent 
with the expected increase of Mw as compared to CRM197. Line numbers indicate CRM197 (1), 
CRM197-1/1 (2), CRM197-1/2 (3), CRM197-2/1 (4), CRM197-2/2 (5), CRM197-3/1 (6), CRM197-3/2 (7), 
CRM197-3/3 (8), CRM197-4/1 (9), CRM197-4/2 (10), CRM197-GAS-PS (11). The numbers on the 
right indicate the numbers of GAS-PS chains attached to CRM197. 
 
The carbohydrate/protein ratio of the conjugates made with native GAS-PS 
ranged from 40 to 50% (wt/wt) corresponding to 2-3 on molar basis; the molar 
carbohydrate/protein ratio of conjugates made with synthetic GAS 
oligosaccharides ranged from 3 to 12 as determined by chemical methods 
(Table I). 
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Conjugate 
code 
Average CHO/Protein Mol/mol Total IgG 
GMT 
AIa, 
M NaSCN 
Chemical 
assays 
MALDI-TOF 
CRM197-1/1 3,4 nd 2911 1,29 
CRM197-1/2 11,6 14,2 5980 0,87 
CRM197-2/1 5,1 nd 1895 1,08 
CRM197-2/2 7,6 7,5 2465 0,64 
CRM197-3/1 5,8 nd 10262 0,81 
CRM197-3/2 7,5 8,8 17780 1,24 
CRM197-3/3 12,2 13,6 639 0,68 
CRM197-4/1 7,6 nd 4063 0,92 
CRM197-4/2 9,2 11,5 2108 0,85 
GAS-PS 2-3 3-4 12086 0,86 
Table I. Glycoconjugate composition and geometric mean titers (GMT) of serum anti-GAS-PS 
antibodies induced after mice immunization. The number of carbohydrate chains per protein was 
calculated from CHO/protein content ratio derived from chemical characterization (HPAEC-PAD, 
MicroBCA) and MALDI-TOF. The avidity index (AI) is expressed as the concentration of NaSCN 
needed to reduce the OD450 by 50%. 
a Pooled sera was analyzed. 
 
Both synthetic and native glycoconjugates were analyzed by MALDI-TOF. As an 
example, a representative mass spectrum of the glycoconjugate CRM197-3/2 and 
CRM197-GAS-PS is shown in Fig. 6. The profile of CRM197-3/2 is composed of a 
polydispersion of Mw centered at 77922.9 corresponding to nine oligosaccharide 
chains per CRM197 molecule; the profile of CRM197-GAS-PS is composed of a 
polydispersion of Mw centered at 87356.4 and 96778.3 corresponding to three 
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and four GAS-PS chains per CRM197 molecule, respectively. A comparison 
between the average glycosylation degree obtained by chemical methods and 
MALDI-TOF is reported in Table I. 
 
Figure 6. MS spectra of the glycoconjugate CRM197-3/2 and CRM197-GAS-PS. 
 
Size-exclusion HPLC analysis of the different conjugates confirmed the SDS-
PAGE results evidencing higher Mw dispersion of CRM197-GAS-PS as 
compared to the synthetic GAS oligosaccharide glycoconjugates (Fig. 7). The 
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glycoconjugates were purified by ultrafiltration, and amounts of unconjugated 
sugar was <10%. 
 
Figure 7. Size-exclusion HPLC profile of the glycoconjugates. 
 
Anti-GAS-PS serum response induced by glycoconjugates 
CD-1 mice received one prime and two boosting doses of the carbohydrate 
antigens protein conjugates (10 µg each). Control groups were immunized either 
with alum only or unconjugated GAS-PS. Sera were collected on day 49, two 
weeks after the third immunization to assess antibody response by ELISA, using 
GAS-PS coupled to HAS as coating reagent. 
All synthetic conjugates regardless saccharide chain length, carbohydrate 
loading and nature of the terminal sugar, were able to induce GAS-PS specific 
IgG in mice (Fig. 8). In general, the antibody response was statistically-lower 
than the one elicited by the CRM197-GAS-PS (P<0.05). A notable exception was 
represented by the conjugates CRM197-3/1 and CRM197-3/2 with a carbohydrate 
loading of 5.8 and 7.5 respectively (Table I), which induced a level of anti-GAS-
PS IgG comparable to that obtained with the native GAS-PS glycoconjugate. On 
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the other hand, CRM197-3/3 with a carbohydrate loading of 12 induced 
significantly lower titres (P<0.05). This observation seems to indicate that for a 
given chain length differences in the glycosylation degree are crucial for the 
induction of an optimal antibody response. 
 
Figure 8. Total IgG antibody titres against GAS-PS. Mice were immunized with unconjugated 
GAS-PS, CRM197-GAS-PS and CRM197-glycoconjugates of synthetic oligosaccharides. The 
graph shows the measurements for one-three groups of 8-16 mice immunized independently; 
conjugates have been injected in seven experiments. Each dot represents single mice sera. 
Horizontal bars indicate GMT meaning of group with 95% confidence interval statistical bars. 
GMT values are shown in Table I. 
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Concerning the influence of the terminal non-reducing sugar on the ability to 
induce a specific antibody response against the native GAS-PS, a direct 
comparison between CRM197-1/1 and CRM197-2/1 (same length, similar loading, 
but different terminal non-reducing sugar) did not reveal a significant difference, 
although GMT induced by the conjugates which contain the oligosaccharides 
terminating with GlcNAc appeared higher (2911 EU/mL vs 1895 EU/mL). Similar 
observation could be made for the pair of the dodecasaccharide 
glycoconjugates CRM197-3/2 and CRM197-4/1 (GMT 17780 EU/mL vs 4063 
EU/mL, respectively). 
Analysis of IgG subclasses revealed that both synthetic oligosaccharides and 
GAS-PS glycoconjugates primarily induced IgG1 (Fig. 9), showing a bias toward 
a Th2 response that could have been an influence of Alum chosen as an 
adjuvant [41, 42]. Avidity of specific IgG detected with tiocyanate elution ELISA 
was not significantly different between the immunization groups (Table I). 
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Figure 9. Distribution of the anti-GAS-PS IgG subclasses on the example of one immunization 
group. 
 
Specificity of anti-GAS-PS polyclonal antibodies 
In order to determine whether carbohydrate chains longer than hexasaccharides 
represent any additional epitopes for antibody recognition, sera from a group of 
mice immunized with CRM197-3 were pooled and depleted for anti-1 antibodies 
by affinity chromatography. Loss of serum reactivity against 1 in ELISA assay 
verified the effectiveness of affinity resin. The depleted serum pool was tested 
further against an HSA conjugate of 3. No response was observed against 3, or 
it was less than 1% of primary anti-3 specific IgG and was not detected due to 
limited sensitivity of the ELISA test. This suggests that although 3 represents an 
elongated structure and contains more repeating units than the hexasaccharide 
1, it did not elicit any antibodies specific for larger epitopes. The same procedure 
was repeated for the serum pool from a group of mice immunized with GAS-PS 
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glycoconjugate. No serum anti-GAS-PS reactivity was observed after depletion 
of antibodies specific for the hexasaccharide 1 indicating equal IgG specificity. 
Protection against i.p. challenge with GAS 
Mice immunized with the three doses of Alum-formulated glycoconjugates (10 
µg) or strain-corresponding M protein (5 µg) were challenged three weeks after 
the last immunization with an appropriate LD90 dose of GAS strain. Mice 
survival was monitored up to 14 days after challenge, but a six day observation 
was optimal to obtain statistically significant protection data. Additionally, with 
the same purpose of the optimization of statistical comparison, protection data 
for different glycoconjugate lots were merged, so that the protection level was 
attributed to the type of carbohydrate antigen but not to the particular loading 
(Table II). 
Immunization with strain-relevant M protein conferred over 80% protection. Mice 
immunized with conjugated carbohydrate antigens had significantly lower 
mortality than control mice immunized with unconjugated GAS-PS (P<0.001). 
CRM197 glycoconjugates conferred similar protection level against M1 strain 
challenge, ranging from 33% to 53% survival. Proof-of-concept of cross-
protection properties was verified for the hexasaccharide 1. CRM197-1 conferred 
56% of protection against the M23 strain challenge, whereas CMR197-GAS-PS 
rescued 34% of animals. 
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Formulated antigen Mice number % of survivals P value 
M1 serotype challenge 
Adjuvant alone 64 15  
GAS-PS 40 13 0,7784 
M1 protein 64 91 <0,0001 
CRM197-GAS-PS 64 47 0,0002 
CRM197-1 40 53 0,0001 
CRM197-2 48 42 0.0026 
CRM197-3 64 33 0.0381 
CRM197-4 40 53 0,0001 
M23 serotype challenge 
PBS 64 11  
M23 protein 32 84 <0.001 
CRM197-GAS-PS 64 34 0,0027 
CRM197-1 16 56 0.0233 
 
Table II. Active immunization studies in mice after i.p. challenge with different M1 and M23 GAS 
serotypes. Three weeks after the final antigen dose, mice were infected with inoculum dose of 
50 cfu/mouse for M23 strain and 2.5x106 cfu/mouse for M1 strain. Survival level indicated 
corresponds to day 6 after the challenge. 
 
Discussion 
The presence of anti GAS-PS antibodies in human sera has been evidenced 
since 1965 (Schmidt, Moore 1965; Karakawa et al. 1965). Subsequently it was 
demonstrated that the level of human GAS-PS-specific antibodies peaks at the 
age of 17 in correspondence to the reduced incidence of GAS infection 
(Zimmerman et al. 1971; Paul 1957), and that these antibodies might play a 
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significant role in the protection from GAS infection (Salvadori et al. 1995). 
Sabharwal et al. (2005) showed that colonization of GAS in the human throats 
inversely correlated with the levels of anti-GAS-PS antibodies, and that mice 
immunized with a GAS-PS-TT conjugate were protected against GAS challenge. 
The above findings in conjunction with the high diversity of M+ GAS serotypes 
encountered in the endemic regions of developing countries, makes GAS-PS, 
which is conserved in most, if not all, strains of this pathogenic bacterium, an 
attractive molecule for the development of a vaccine against Group A 
Streptococcus infections. Some concerns about GlcNAc-containing vaccines 
have been voiced due to a possible role of anti-GAS-PS antibodies in the 
development of GAS infection sequela, like acute rheumatic fever or 
Sydenham’s chorea (Malkiel et al. 2000; Kirvan et al. 2006; Shikhman et al. 
1993). However the antibodies induced in mice by GAS-PS-TT conjugates did 
not react with several types of human tissues (Sabharwal et al. 2006). 
In the present thesis I have described the synthesis, conjugation, antigenic and 
immunogenic properties of synthetic GAS core oligosaccharides. The study was 
designed to address several fundamental questions: i) can minimal GAS-PS 
core antigen determinants to elicit a protective antibody response? ii) what 
structural features influence the immunogenicity of synthetic antigens? iii) how 
do oligosaccharide-protein conjugates compare to isolated GAS-PS conjugates 
as far as immunogenicity and immunoprotection in vivo are concerned? 
Synthetic carbohydrate-based anti-GAS vaccine candidate was directly 
compared to the immunogenic and protective properties of a conjugate made 
with the native GAS-PS. 
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The synthetic approach for the production of carbohydrate antigens provided 
pure material of well-defined structure in contrast to isolated GAS-PS that varies 
in molecular weight and is contaminated with the poly-rhamnoses. Conjugation 
of the carbohydrates with a single reactive group per molecule allowed for 
efficient preparation of the glycoconjugates with one configuration and did not 
lead to the formation of high molecular weight aggregates with intermolecular 
linkages (Fig. 4-7). The composition of these glycoconjugates was detected by 
physico-chemical methods, and facilitated the development of standardized 
criteria for reliable prediction of their immunogenic properties. 
CRM197 conjugates with the native GAS-PS and with four different synthetic 
GAS oligosaccharides varying in length and composition of the reducing end 
were prepared and characterized by physico-chemical methods (Fig. 4-7, Table 
I). CRM197 conjugates of both synthetic oligosaccharides and native GAS-PS 
elicited high levels of serum GAS-PS-specific IgG with a bias towards IgG1 
production (Fig. 8, 9). Carbohydrate antigen formulation with Alum was suitable, 
as it favored a Th2 response that is preferred for a vaccination against 
extracellular pathogens (Bloom, Lambert 2003; Kalinski, Moser 2005; Shikhman 
et al. 1993). The synthetic oligosaccharides and GAS-PS were the same 
antigenically and induced antibodies with hexasaccharide paratope. 
Subsequently, presence of these antibodies were found to be a correlate of the 
protective immunity against GAS M1 serotype, one of the common agents of 
invasive and toxic streptococcal diseases (Courtney et al. 2009; Cunningham 
2000; Klenk et al. 2007; Stanley et al. 1995). The conjugates made with 
synthetic GAS oligosaccharides were able to induce in mice a significant level of 
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protection against M1 strain challenge ranging from 33 to 53% which is 
comparable to the protection of 47% obtained by the conjugate with the native 
polysaccharide (Table II). Cross-protection paradigm was revealed with GAS 
M23 serotype challenge which resulted in significant protection level of 56% 
induced by the synthetic conjugate CRM197-1 as compared to the 34% induced 
by CRM197-GAS-PS. 
Trying to establish a few variables related to the immunogenicity of the synthetic 
GAS oligosaccharides conjugates, the attention was focused onto the 
saccharide chain length, the glycosylation degree and the non-reducing sugar. 
Our results show that a saccharide chain length of six, corresponding to the 
minimal size of the epitope, is sufficient to elicit a protective response 
characterized by antibodies which recognize the native polysaccharide. 
Concerning the glycosylation degree, a loading between 6 and 8 carbohydrate 
chains has been found optimal for the glycoconjugates with dodecasaccharide 
3, while higher loading of 12 chains led to a decrease in the immunogenicity 
(Table I). Pozsgay et al. (Pozsgay et al. 1999), studying the immunogenicity of 
glycoconjugates containing synthetic Shigella dysenteriae type 1 
oligosaccharides of different length and at various loading, concluded  that the 
saccharide length and the glycosylation degree do not play independent roles 
and that, for each chain length, the maximum antibody response is obtained with 
a given combination of the two variables. Accordingly, it may be supposed that 
the carbohydrate should not be overloaded onto the protein, because it can 
“shield” T/B-cells epitopes essential for efficient immunogenicity of the carrier, 
but still should be present in a sufficient amount to promote B-cell receptor 
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clustering. It is likely that the above observation is valid also in the case of the 
GAS synthetic conjugates presented in this study, and it might be a general rule. 
Therefore, in order to compare the immunogenicity of conjugates with different 
chain lengths it seems appropriate determining for each of them the best 
combination “chain length/loading”. 
The non-reducing terminal sugar may also play a role in the immunogenicity of 
synthetic antigens since recent study on Shigella dysenteriae type 1 O-specific 
oligosaccharide and Streptococcus pneumonia type 14 capsular polysaccharide 
demonstrated that an increase in carbohydrate-specific antibody response was 
associated with the exposure of GlcNAc and galactose, respectively, on the 
nonreducing end of the oligosaccharide antigen (Safari et al. 2008; Pozsgay et 
al. 2007). GlcNAc residue on the non-reducing terminus contributed to the 
immunogenicity of the GAS-PS core epitope as evidenced by the relatively 
higher GMT induced by glycoantigens 1 and 3 (Table I). 
In conclusion, it was possible to establish the conditions in which 
glycoconjugates with synthetic GAS-PS structures have equal or better 
immunogenicity than native GAS-PS. The glycoconjugate CRM197-3/1 and 
CRM197-3/2, exposing optimal number of dodecasaccharides containing GAS-
PS antigenic core and immunodominant GlcNAc sugar on the non-reducing 
terminus, elicited in mice specific IgG titres of 10262 and 17780 EU/mL, 
respectively, as compared to 12082 EU/mL induced by CRM197-GAS-PS, 
demonstrating that by means of rational design it is possible to design an 
optimized glycoantigen. 
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In conclusion this study has enlarged the previous knowledge on the 
immunogenicity and protective properties of GAS carbohydrate antigens 
(Michon et al. 2005; Reimer et al., 1992; Sabharwal et al. 2006) by 
demonstrating that synthetic oligosaccharides conjugated to CRM197 as protein 
carrier could elicit in animal model similar level of antibodies and protection to 
those induced by a conjugate with the purified GAS cell wall polysaccharide. 
The synthetic approach toward the development of a conjugate vaccine against 
Group A Streptococcus infection appears therefore a viable option which 
deserves further studies and optimization. 
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Conclusion 
Vaccination represents an efficient, safe and cost-effective way for prevention 
and prophylaxis of devastating human diseases. Carbohydrate-based conjugate 
vaccines are included into the children immunizations schedule worldwide, and 
due to an active research in the field new vaccine candidates are being 
generated continuously (Hecht et al. 2009). A major contribution to such 
success was made by the detailed investigation of the structure of natural 
carbohydrates of pathogenic agents and progress in the development of 
conjugation methods. During the past decade, advances in the chemical 
synthesis of oligosaccharides have brought synthetic approach applied to the 
carbohydrate-based vaccines to a leading position in the field. The prior-art 
knowledge on the structure of protective carbohydrate epitopes of group A 
Streptococcus and human immunodeficiency virus and accessibility of the 
synthetic oligosaccharides containing the antigenic determinants of those 
epitopes provided basis for the present work. 
Conventionally, carbohydrate antigens for vaccine development have been 
isolated from biological sources. Application of synthetic approach procures 
pure, homogeneous oligosaccharide antigens of homogenous structure, 
rationally planned to contain immunodominant saccharide composition and 
single-site incorporated reactive groups for covalent conjugation. Such 
oligosaccharides represent single molecular species and thereby being good 
starting compounds for the preparation of well-defined vaccines. A large set of 
physicochemical methods served to assess the conjugation outcome and 
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characterize the composition of obtained neoglycoconjugates. This analysis 
facilitated the development of standardized criteria for reliable prediction of their 
immunogenic properties. In the present work mentioned advantages of synthetic 
oligosaccharides and analytical tools have been applied to the research on the 
structural requirements of the protective carbohydrate epitopes of efficient group 
A Streptococcus and HIV glycoconjugate vaccines. The focus of the study was 
on the generation, characterization and immunogenic evaluation of the 
carbohydrate antigens of the mentioned pathogens. 
Flexible polyamidoamine (PAMAM) scaffold have been exploited to generate 
four- and eight-valent sugar clusters of HIV-1-related oligomannose antigens 
Man4, Man6 and Man9. Oligomannoses for the development of our glycoantigens 
were chosen on the basis of biochemical, biophysical and crystallographic 
evidences available in the literature (Calarese et al. 2003; Calarese et al. 2005; 
Pashov et al. 2005; Sanders et al. 2002; Wang et al. 2008). The multivalent 
presentation of oligomannoses aimed to mimic the native epitope of the 
mannose-specific broadly neutralizing antibody 2G12. Clusterization indeed 
increased the avidity of Man4 and Man9 to 2G12. The synthetic glycodendrons 
covalently coupled to the protein carrier CRM197 and formulated with the 
adjuvant MF59 were used to immunize two animal species. Oligomannose-
specific IgG antibodies were generated, however, the antisera failed to 
recognize recombinant HIV-1 gp120 proteins. This study made contribution to 
the global knowledge on carbohydrate-based HIV-related antigens, structural 
requirements of the oligomannoses to be used for their construction and using of 
PAMAM scaffolds as suitable multivalent carriers. The result indicates that 
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further structural vaccinology work is needed to identify an antigen presentation 
that closely matches in vivo the structure of the epitope mapped by 2G12. 
The study on GAS synthetic glycoconjugate vaccine demonstrates the value of 
synthetic oligosaccharides for carbohydrate conjugate vaccine development 
along with other published studies (Benaissa-Trouw et al. 2001; Chong et al. 
1997; Jansen et al. 2001; Liu et al. 2006; Pozsgay et al. 1999; Pozsgay et al. 
2007; Ragupathi et al. 2006; Robbins et al. 2009; Safari et al. 2008; Saksena et 
al. 2007; Schofield et al. 2002; Verez-Bencomo et al. 2004). A series of hexa- 
and dodecasaccharides were designed based on the GAS-PS structure and 
prepared by chemical synthesis. The synthetic oligosaccharide-CRM197 
conjugates served to explore the impact of antigen length and the nature of the 
residue on the non-reducing end on immunogenicity. The synthetic 
oligosaccharides conjugated to CRM197 elicited a similar level of immune 
response when compared to isolated GAS-PS conjugated to CRM197 and 
conferred comparable levels of immunoprotection in an established challenge 
system in mice using two of the main circulating GAS strains. The obtained 
immunoprotection results lay the foundation for the future clinical evaluation of 
oligosaccharide conjugate vaccine candidates. The use of oligosaccharides 
representing the conserved GAS polysaccharide is a promising approach to 
address the highly diverse nature of M+ GAS serotypes encountered in the 
endemic regions of developing countries. 
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This thesis demonstrates that rational design of carbohydrate-conjugate 
vaccines is a potent tool and is beginning to impact vaccine development and 
regulatory processes. 
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Material and Methods 
Chapter 1 
Materials 
Synthetic high-mannose oligosaccharides, equipped with an amino linker, were 
purchased from Ancora Farmaceuticals (MA, USA); their characterization data 
can be found in Online resource 3. PAMAM4 and PAMAM8 were kindly provided 
by professor G. Catelani (University of Pisa, Italy). CRM197 were internally 
produced in Novartis V&D, Siena, Italy. The 2G12 antibody, HIV proteins gp140 
UG37 (clade A strain 92/UG/037, a.a. 32-662, NCBI protein database No. 
AAC97548, catalog no. ENV001) was purchased from Polymun Scientific 
(Vienna, Austria). HIV gp120 Bal (a.a.32-518, GenBank No. M68893, catalog 
no. IT-001-002p), gp120 R2 (a.a.41-520, GenBank No. AF128126, catalog no. 
IT-001-0029p), and gp120 JRFL (a.a.34-518, GenBank No. U63632, catalog no. 
IT-001-0024p) were purchased from Immune Technology Corp. (New York, US). 
Polymun and Immune Technology recombinant proteins are expressed in CHO 
and 293T cells, correspondingly. Biotinylated Galantus Nivalis Lectin (GNL) was 
purchased from Vector Laboratories (CA, US). 
Analytical methods 
Total saccharide concentration was determined by HPAEC-PAD analysis (ICS-
3000 Dionex system). Briefly, oligomannose carbohydrate preparation was 
hydrolyzed in 2 M trifluoracetic acid for 2h at 100°C, dried and then dissolved in 
water. 20 µL of sample were injected into CarboPac PA1 analytical column (250 
mm x 4 mm i.d., Dionex) with CarboPac PA1 guard column (50 mm x 4 mm i.d., 
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Dionex). Isocratic separations were performed using a 30-min 16 mM NaOH 
followed by a 5-min 500 mM NaOH regeneration step and 15-min re-
equilibration, set to a flow rate of 1.0 mL min−1. Monosaccharide peaks were 
detected directly by using quadruple-potential waveform pulsed amperometry on 
a gold working electrode and an Ag/AgCl reference electrode. Raw data were 
elaborated on Chromeleon 6.8 chromatography software (Dionex) with 
application of 0.5-10 µg/mL mannose calibration curve. Rapid hexose 
quantification was performed by Phenol-H2SO4 method (Scott RW et al. 1967).  
Protein concentration was determined by Micro BCA kit (Thermo Fisher 
Scientific). 
ESI Q-TOF MS analyses 
Analyses by direct sample injection were performed  in a Micromass Q-Tof 
Micro system (Waters MS Technologies, UK) diluting the samples 1:200 (v/v) or 
less in 0.1% formic acid, 1:1 (v/v) acetonitrile:water. For LC-Mass analyses  the 
Q-tof Micro system was coupled to an UPLC system (ACQUITY UPLC System, 
Waters, UK). Chromatographic separations of samples diluted in water were 
performed on 2.1 mm i.d. x 50 mm ACQUITY BEH C18 1.7 µm column (Waters 
Corp., USA). Elution was performed with a linear gradient of 2-50% B for 8 min, 
then 50%-100% B for 1.5 min, reconditioned 2% B for 2 min each cycle, where 
A = water with 0.1% formic acid and B = acetonitrile with 0,1% formic acid. Each 
cycle duration was 13 min at a flow rate 0.4 mL/min. 10 µL aliquots of sample 
were loaded. HPLC peak detection was performed by total ion current and best 
peak intensity measurement. 
TOF MS analysis was performed operating in positive ion mode (ESI). The 
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nebulization gas was set to 800 L/h at a temperature of 250°C, the cone gas set 
to 50 L/h and the source temperature set to 100°C. The capillary and cone 
voltages were 3500 V and 30 V, respectively. The Q-Tof Micro was operated 
with collision energy of 5 V. The data acquisition rate was set to 0.1 s with a 0.1 
s inter-scan delay. The raw data were analyzed by the Micromass MassLynx 
applications manager Version 1.0, using Maxent3 for deconvolution (Waters, 
UK). The general strategy for assigning peaks to glycodendrons involved: 1) 
identification of a pair or series of ions in the spectra separated by the mass of a 
mannose saccharide (162 Da); 2) assigning individual peaks of these 
distributions. 
PAMAM cluster synthesis and purification 
In a typical experiment Man4, Man6 or Man9 synthetic oligosaccharide with a six-
carbon amino linker at the reducing end (20 µmol) were treated with 
disuccinimidyl adipate (200 µmol) in 0.3 mL DMSO containing 43 µmol of 
triethylamine. After 2 hours of vigorous stirring the activation of sugar was 
checked by TLC performed on aluminium plates coated with silica gel 60 Å F254 
(Merck) with detection by charring with 10% ethanolic H2SO4. The activated 
oligosaccharide was purified by precipitation in 9 volumes of ethylacetate; the 
pellet obtained by centrifugation was washed two times with 1 mL of 
ethylacetate and vacuum dried. 
The succinimidyl-activated oligosaccharides were then coupled to PAMAM4 and 
PAMAM8 with stoichiometry of 8:1 and 20:1 mol/mol, respectively. The reaction 
was carried out in 0.1 mL DMSO containing 20 µL/mL triethylamine at RT. 
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Cluster formation was monitored in process by HPLC-ESI MS analysis and in 
some cases a further addition of activated oligosaccharide was performed in 
order to maximize the formation of the desired cluster. The reaction mixture was 
then lyophilized and dissolved in water. The excess of unreacted 
oligosaccharide was removed by hydrophobic interaction on a C4 column (0.5 
mL resin, Bioselect, Grace Vydac) activated with methanol and preconditioned 
with water and eluted with a stepwise gradient of methanol (0-80% in water). 
Fractions of 2 mL were analyzed by TLC and ESI Q-TOF MS; and those 
containing fully-substituted PAMAM were dried to remove methanol. The yields 
for cluster formation and purification varied from 46-77% for PAMAM4-based 
dendrons and 28-30% for PAMAM8-based dendrons 
PAMAM4-Boc ESI MS m/z (C37H76N14O8): found 845.56 ((M+H)+, calc. 845.60), 
423.27 ((M+2H)2+, calc. 423.31). PAMAM8-Boc ESI MS m/z (C37H76N14O8): 
found 879.70 ((M+2H)2+, calc. 879.62), deconv. 1758.37 ((M+H)+, calc. 
1758.24). Man4PAMAM4-Boc ESI MS m/z (C181H320N18O100): found 1450.48 
((M+3H)3+, calc. 1450.54), 1458.80 ((M+3H+Na)3+, calc. 1457.87), 1396.45 
((M+3H-Man)3+,calc. 1396.49), deconv. 4347.36 ((M+H)+, calc. 4347.06), 
4369.24 ((M+Na)+, calc. 4369.04), 4185.32 ((M+H-Man)+, calc. 4185.01). 
Man9PAMAM4-Boc ESI MS m/z (C301H520N18O200): found 1898.62 ((M+4H)4+, 
calc. 1898.87), 1904.21 ((M+3H+Na)4+, calc. 1904.36), 1858.09 ((M+4H-
Man)4+,calc. 1858.33), deconv. 7587.53 ((M+H)+, calc. 7588.12), 7610.38 
((M+Na)+, calc. 7610.10), 7425.80 ((M+H-Man)+, calc. 7426.06). Man4PAMAM8-
Boc HPLC tR=2.728 min; ESI MS m/z (C365H644N38O200): found 1754.03 
((M+5H)5+, calc. 1754.06), 1721.46 ((M+5H-Man)5+, calc. 1721.63), 1689.18 
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((M+5H-2 Man)5+, calc. 1689.20), 2192.33 ((M+4H)4+, calc. 2192.32), 2152.64 
((M+4H-Man)4+, calc. 2151.79), 2111.22 ((M+4H-2Man)4+, calc. 2111.25), 
deconv. 8761.17 ((M+H)+, calc. 8761.15), 8599.08 ((M+H-Man)+, calc. 8599.09), 
8437.02 ((M+H-2 Man)+, calc. 8437.04). Man9PAMAM8-Boc HPLC tR=2.172 min; 
ESI MS m/z (C605H1044N38O400): found 2179.85 ((M+7H)7+, calc. 2179.72), 
2156.65 ((M+7H-Man)7+, calc. 2156.55), 2133.57 ((M+7H-2 Man)7+, calc. 
2133.39), 2542.94 ((M+6H)6+, calc. 2542.83), 2515.60 ((M+6H-Man)6+, calc. 
2515.81), 2488.67 ((M+6H-2Man)6+, calc. 2488.79), deconv. 15240.77 ((M+H)+, 
calc. 15243.26), 15079.57 ((M+H-Man)+, calc. 15081.21), 14918.34 ((M+H-2 
Man)+, calc. 14919.15). 
Competitive Surface Plasmon resonance 
The experiments were carried out with a BiaCore X100 system in a HBS-EP 
buffer (10 mM HEPES, 150 mM NaCl, 0,005% surfactant Tween 20, pH 7.4). 
For coupling two flow cells of a CM5 chip (GE Healthcare) were activated by 
injection of EDC/NHS mixture for 7 min at 10 µL/min, followed by injection of 10 
µg/mL gp140 UG37 in sodium acetate pH 4.5 over the channel two until the 
target level was reached; both were then blocked with 1.0 M ethanolamine pH 
8.5 for 7 min at 10 µL/min. Final immobilization level of gp140 was 6800 RU. 
2G12 solution with and without carbohydrate inhibitors was injected over both 
channels, and the binding profile was obtained by subtraction of the blank signal 
in channel one from the gp140 UG37 signal in channel two. 2 µg/mL 2G12 was 
incubated with 0-1200 µM carbohydrate inhibitor for 15 minutes at 37°C before 
the analysis. Analyte was injected at 10 µL/min for 4 min, followed by 6 min 
dissociation and 30 sec of regeneration with 10 mM glycine, 3M NaCl pH 2.0. 
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Sensorgrams were elaborated on the Biacore X100 software package. Inhibition 
percentage was calculated as (Sno inhibitor – Sinhibitor)*100/Sno inhibitor, where S is the 
stability level with reference subtraction (buffer sample). The stability level 
corresponds to the RU signal at 270 sec and was chosen for the calculation as 
less influenced by the analyte bulk effect in comparison to the binding level 
(measured 240 sec) [46]. Inhibition curve was fitted on the Graphpad Prism 
software using variable slope model (Graphpad Prism Inc.). Two data points, 
(x1, y1) and (x2, y2), adjacent to the 50% inhibition titer were chosen, where x is 
inhibitor concentration and y is corresponding inhibition level. IC50 value was 
calculated according to the equation IC50=
( )
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Conjugation of oligomannose and oligomannose glycodendrons to CRM197 
t-Boc protecting groups in glycodendrons were cleaved by reaction in 20% 
trifluoracetic acid (TFA) for two hours at RT. The removal of t-Boc was verified 
by MS analysis, and the samples were extensively dried under vacuum to 
remove TFA. Monovalent oligosaccharides or deprotected glycodendrons were 
then activated with disuccinimidyl adipate and purified according to the 
procedure reported above. The activated oligosaccharides were then conjugated 
in 200 mM sodium phosphate pH 7.2 to CRM197 (10-20 mg/mL) with a 
stoichiometry of 30:1 or 40:1 glycodendron:protein (mol/mol). After overnight 
incubation at 37°C, conjugates were then purified from the excess of 
unconjugated carbohydrate using ultrafiltration spin columns with 30 kDa or 50 
kDa cut-off (Vivaspin, Sartorius). The purified glycoconjugates were analyzed for 
their protein and carbohydrate content and by SDS-PAGE. 
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Conjugation of Man9 to HSA via diethyl squarate chemistry 
The synthetic oligosaccharide (20 mmol) was treated with 3,4-diethoxy-3-
cyclobuten-1,2-dione (150 mmol) in 0.1 mL 1:1 vol ethanol:100 mM sodium 
phosphate pH 7.0. After overnight incubation with vigorous stirring activation of 
sugar was checked by TLC. The excess of linker was removed by hydrophobic 
interaction C18 column (C18-E, Strata, Phenomenex) after 3 CV water and 3 CV 
ethylacetate washing steps with final methanol elution. Target fractions were 
dried to remove methanol. The activated oligosaccharides were conjugated in 
200 mM sodium borate pH 9.2 to CRM197 (10-20 mg/mL) with a stoichiometry of 
30:1 (mol/mol). Purification and characterization was performed as described 
above. This glycoconjugate has been used in ELISA as coating reagent for anti 
Man9 antibodies determination.  
Animal immunizations 
Animal experimental guidelines set forth by the Novartis Animal Care 
Department were followed in the conduct of all animal studies. Groups of 2-4 
female white Zealand rabbits (2 kg weight) were immunized on days 1, 21 and 
35 with 5 or 20 µg of carbohydrate antigens or with PBS both formulated 1:1 
(v/v) with MF59 and delivered in a final volume of 250 µL , intramuscularly into 
both quadriceps. Sera were collected on days 20, 34 and 42. 
Groups of 8 female Balb/c mice were immunized on days 1, 14 and 28 with 1 µg 
of carbohydrate antigens or PBS both formulated with MF59 and delivered in a 
volume of 150 µL by subcutaneous injection. Sera were collected on day 0, 27 
and 42. 
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ELISA 
a) Determination of anti Man9-specific antibodies. 96-well Maxisorp plates 
(Nunc, Thermo Fisher Scientific) were coated with 100 µL/well of a 1 µg/mL 
solution of Man9-squarate-HSA in PBS. Plates were incubated overnight at 
+4°C, then washed three times with TPBS (PBS with 0,05% Tween 20, pH 7.4) 
and blocked with 100 µL/well of 2% BSA (Sigma-Aldrich) for 1 hour at 37°C. 
Subsequently each incubation step was followed by triple TPBS wash. Sera, 
prediluted 1:25-1:1000 in 2 % BSA-TPBS, were transferred into coated- plates 
(200 µL) and then serially two-fold diluted followed by 2h incubation at 37°C. 
Then 100 µL/well of 1:10000-1:20000 diluted appropriate alkaline phosphatase-
conjugated secondary antibody (Sigma Aldrich) were added and plates 
incubated for 1h at 37°C. Subsequently 100 µL/well of 1 mg/mL pNPP disodium 
hexahydrate (Sigma Aldrich) in 1M diethanolamine (pH 9.8) was distributed onto 
plates. After 30 minutes of development at RT plates were read at 405 nm with a 
microplate spectrophotometer. Antibody titres were defined as the reciprocal of 
those dilutions that gave an optical density (OD) higher than three times the 
average OD of preimmune or mock-immunized sera. 
b) Evaluation of anti HIV-1 gp120 and anti-CRM specific antibodies. 
In order to evaluate the ability of rabbit or mouse immune sera to recognize HIV-
1 gp120 glycoproteins or CRM197, the ELISA protocol described above has been 
repeated but using as coating 100 ng/well of three different HIV-1 clades Bal, 
JRLF and R2, and CRM197. 
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Chapter 2 
Materials 
Synthetic GAS oligosaccharides, equipped with an amino linker, were 
purchased from Ancora Pharmaceuticals (Medford, USA). CRM197 was internally 
produced in Novartis V&D, Siena, Italy. 
Bacterial strains and culture conditions 
Streptococcal strain GAS SF370 M1 was obtained from University of Siena, 
Italy. Streptococcal strain M1 3348 was obtained from Istituto Superiore di 
Sanità, Rome, Italy. GAS M23 2071 was purchased from Deutsche Sammlung 
von Mikroorganismen und Zellkulturen GmbH (German Collection of 
Microorganisms and Cell Cultures). Bacterial strains were stored at −80°C and 
routinely grown in Todd-Hewitt broth (Difco) at 37°C until mid-log phase. 
Analytical methods 
Total saccharide concentration was determined by HPAEC-PAD analyses (ICS-
3000 Dionex system). Briefly, the GAS-PS preparation was hydrolyzed in 4 M 
trifluoracetic acid for 2 h at 100°C, dried and dissolved in water. 20 µL samples 
were injected into CarboPac PA1 analytical column (250 mm x 4 mm i.d., 
Dionex) with CarboPac PA1 guard column (50 mm x 4 mm i.d., Dionex). 
Isocratic separations were performed using a 15-min 50 mM NaOH followed by 
a 5-min 500 mM NaOH regeneration step and 10-min re-equilibration, set to a 
flow rate of 1.0 mL min−1. Monosaccharide peaks were detected directly by 
using quadruple-potential waveform pulsed amperometry on a gold electrode 
and an Ag/AgCl reference electrode. Raw data were elaborated on a 
Chromeleon 6.8 chromatography software (Dionex) with application of 0.5-10 
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µg/mL GlcNAc calibration curve. Rapid hexose quantification was achieved by 
Phenol-H2SO4 method (Scott RW et al. 1967). Unconjugated saccharide 
concentration was analyzed by passing 1 mL of purified neoglycoconjugate 
preparation at 10 µg/mL saccharide concentration through C4 hydrophobic 
interaction column (0.5 mL resin, Bioselect, Grace Vydac). Unconjugated 
carbohydrate was eluted with 1 mL of 20% acetonitrile in water and 
subsequently estimated by HPAEC-PAD analysis. Protein concentration was 
determined by MicroBCA and Bradford protein assay kit (Thermo Fisher 
Scientific). Hyaluronic acid concentration was determined using test kit 
(Corgenics). DNA concentration was determined by spectrophotometric OD 
method (Haque et al. 2003). Size-exclusion HPLC for glycoconjugate profiling 
was done with TSK Gel G4000SW column on Ultimate-3000 HPLC system 
(Waters). All the samples were eluted at 0.5 mL/min flow with a mobile phase 
buffer containing 0.1 M sodium phosphate, 0.1 M sodium sulfate, 5% 
acetonitrile, pH 7.2. 
Spectroscopy and chromatography  
NMR analyses:  Lyophilized CHO samples were dissolved in deuterium oxide 
(D2O, 99.9% atom D, Aldrich) to produce a uniform solution. 1H NMR 
experiments were recorded at 25°C on a Bruker Avance™ 600 MHz 
spectrometer, using a 5-mm broadband probe (Bruker). The XWINNMR™ 
software package (Bruker) was used for data acquisition and processing.  32k 
data points were collected over a 10 ppm spectral width for the proton spectra. 
The transmitter was set at the HDO frequency, which was also used as 
reference signal (4.79 ppm). 1D proton NMR spectra were collected using a 
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standard one-pulse experiment. Determination of dn/dc and SEC-MALLS 
analysis: SEC-MALLS analysis was performed using a TSK-Gel G2000SWXL 
column (Tosoh Bioscience) coupled with an Alliance 2695 solvent delivery 
module (Waters, Millipore). The polysaccharide sample was injected at the 
concentration of 11.6 mg/mL in 10 mM NaPi pH 7.0 and eluted at the flow rate of 
0.5 mL/min. Scattered light intensities were measured using a Dawn EOS multi-
angle light scattering photometer (Wyatt Technology Corp.). Data were collected 
and processed using the software ASTRATM (Wyatt technology Corp.). The 
absolute molecular mass was determined according to the equation R(θ) = 
K*McP(θ)[1−2A2McP(θ)], where R(θ) is the excess Rayleigh ratio, K* the 
polymer constant for a particular scattering system, M the molecular mass, c the 
solute concentration (g/mL), P(θ) the form factor related to the mean square 
radius rg of the particle and A2 is the second virial coefficient, a measure of 
solute-solvent interaction, which to a first approximation can be taken as zero 
(Tanford 1961). dn/dc value of GAS polysaccharide was measured using an 
interferometric refractometer Optilab DSP (Wyatt Technology Corp.) pre-
calibrated with NaCl samples. A series of six different polysaccharide samples 
with concentration ranging from 0.039 to 1.158 mg/mL in 10 mM NaPi pH 7.0 
was injected through the refractometer, starting with the lowest concentration. 
The dn/dc value was calculated using the software DNDCTM (Wyatt Technology 
Corp.). MALDI-TOF mass spectra of CRM197 and glycoconjugates were 
recorded by an UltraFlex III MALDI-TOF/TOF instrument (Bruker Daltonics) in 
linear mode with positive ion detection. All the samples for analysis were 
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prepared by mixing 1 µL product and 1 µL of sinnapinic acid matrix in 0.1% TFA 
and 30% acetonitrile. 1 µL of each mixture has been deposited on samples 
plate, dried at room temperature for 10 min and subjected to the spectrometer. 
Isolation of native GAS-PS 
GAS-PS was released from bacterial culture by reductive acidic treatment as 
previously described (Sabharwal et al. 2006) and purified by several steps of 
ultrafiltration and chromatography. Briefly, acid-treated cell pellet suspension 
was clarified by orthogonal filtration using 0.65 µm pore glass fiber filter 
(Sartopure GF2 capsule, Sartorius). Then permeate was diafiltrated with 30K 
cut-off membrane (Hydrosart, Sartorius) against 1M NaCl and water. Obtained 
material was additionally purified by anion exchange chromatography (Q-
Sepharose FF resin, AKTA systems, GE Healthcare). PS-containing fractions 
were concentrated by TFF using 5K membrane (Sartorius). 
Preparation and characterization of glycoconjugates 
In a typical experiment synthetic oligosaccharide (1 µmol) was treated with 
disuccinimidyl adipate (10 µmol) in 1.5 mL DMSO containing 0.01 mL 
triethylamine. After 2 h of vigorous stirring, chromatography of the crude mixture 
in silica gel (0.035-0.70 mm, 60 Å, Sigma-Aldrich) in a gradient of 0-70% 
methanol in ethylacetate yielded activated oligosaccharide. Fractions were 
analyzed by TLC (ethylacetate-methanol 1:1) with detection by charring with 
10% ethanolic H2SO4 and ninhydrin (1.5 mg/mL in 38:1.75:0.25 1-
BuOH/H2O/HOAc). Fractions containing pure activated CHO were merged with 
subsequent determination of active ester groups (yield 13-39%) (Pitner et al. 
2000). Alternative method of the activated oligosaccharide purification consisted 
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in precipitation of the reaction mixture in 9 volumes of ethylacetate; the pellet 
obtained by centrifugation was washed two times with 1 mL of ethylacetate and 
vacuum dried (yield 42-51%). A conjugation stoichiometry of 30:1 active ester 
group mol/ protein mol was applied. A solution of CRM197 in 100 mM NaPi buffer 
pH 7.0 (10-20 mg/mL) was added to the dried activated oligosaccharide. The 
mixture was incubated ON at RT, mixing very gently with a magnetic stirrer. 
Native GAS-PS was conjugated to lysine residues of CRM197 by reductive 
amination in the presence of NaBH3CN (Jennings, Lugowski 1981). The reaction 
was carried out in 200 mM NaPi pH 8.0 with stoichiometry 4:2:1 (wt:wt:wt) of 
CHO:NaBCNH3:protein. The solution was 0.22 µm filtered and kept at 37°C for 2 
days. Conjugates were purified from excess of unconjugated carbohydrate using 
ultrafiltration spin columns with 30K or 100K cut-off (Vivaspin, Sartorius). 
Active immunizations 
Animal experimental guidelines set forth by the Novartis Animal Care 
Department were followed in the conduct of all animal studies. Groups of 8-16 
female CD-1 mice (5-6 week old) were immunized on days 1, 21 and 35 with 10 
µg of carbohydrate antigen (100 µL final volume). Adjuvant alone or non 
conjugated polysaccharide (10 µg) were used for negative control groups, while 
strain-specific M protein (10 µg) was used for positive control groups. Antigens 
were formulated with aluminium hydroxide before injection. Sera samples were 
collected before the first immunization and two weeks after the third 
immunization (day 49). 
Serum ELISA 
Titration of carbohydrate-specific antibodies was performed on individual sera 2 
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weeks after the last immunization. For that purpose 96-well Maxisorp plates 
(Nunc, Thermo Fisher Scientific) were coated with 100 µL/well of PBS-diluted 1 
µg/mL HSA conjugates of GAS-PS. Plates were incubated for 3 hours at room 
temperature, then washed three times with TPBS (PBS with 0.05% Tween 20, 
pH 7.4) and blocked with 100 µL/well of 2% BSA (Sigma-Aldrich) for 1 h at 
37°C. Subsequently each incubation step was followed by triple TPBS wash. 
Serum samples were initially diluted 1:500-1:1000 in 2 % BSA in TPBS, 
transferred into coated-blocked plates (200 µL) and serially two-fold diluted 
followed by 2 h incubation at 37°C. Then 100 µL/well of 1:2000-1:5000 diluted 
alkaline phosphatase-conjugated goat anti-mouse IgM (µ-chain specific, Sigma 
Aldrich), IgG or given IgG subclass (whole molecule, Sigma Aldrich) antibody 
were added and left for 2 h at 30°C. 100 µL/well of 3 mg/mL pNPP disodium 
hexahydrate (Sigma Aldrich) in 1M diethanolamine (pH 9.8) was distributed onto 
plates to visualize the amount of bound alkaline phosphatase. After 10 minutes 
of development at RT plates were read with a microplate spectrophotometer at 
405 nm. Antibody titres are those dilutions that gave an optical density (OD) 
higher than the mean plus five times the standard deviation of the average OD 
obtained in the preimmune sera. The titres were normalized with respect to the 
reference serum and expressed in ELISA units (EU) per mL. Reference serum 
was obtained from GAS CHO glycoconjugate immunized mice. The thiocyanate 
elution ELISA for affinity studies is described elsewhere (McCloskey et al. 1997). 
Absorbance value of sera without NaSCN was at least 1.0. 
Immunoadsorption of anti-hexasaccharide antibodies from mice sera 
HSA conjugate (100 µg) of oligosaccharide 1 was coupled to 200 µL NHS-
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activated sepharose resin (GE Healthcare) following the manufacturer 
instructions. Excess of active groups on the resin was blocked with 0.5 M 
ethanolamine, 0.5 M NaCl, pH 8.3. Operations with small amount of resin were 
performed in clarification spin column (Vivapure, Sartorius) with 0.22 µm 
membrane filter. Resin was equilibrated in PBS, incubated with 1:20 PBS-diluted 
mice sera for 10 min and then spun. The flow through was cycled five times 
through the column. Between cycles resin was regenerated by 100 mM glycine, 
pH 2.7 and re-equilibrated with PBS. 1:100 diluted sera from flow-through 
fraction was tested for its reactivity against HSA conjugates of 1, 3 and GAS-PS 
in ELISA assay. Reference anti-CRM197 titration was performed to allow the 
recalculation of antibody titers due to unspecific absorption. 
In vivo protection assays 
Immunized animals were intraperitoneally (i.p.) challenged on day 56, three 
weeks after the last immunization with a bacterial dose ranging from 50 (for M23 
2071 strain) to 2.5x106 (for M1 3348 strain) colony forming units (cfu) per mouse 
(lethal dose 90, LD90). Animals were monitored on a daily basis and euthanized 
when they exhibit defined humane endpoints that were pre-established for the 
study in agreement with Novartis Animal Welfare Policies. Bacterial cultures for 
infection experiments were grown in Todd-Hewitt broth until mid-log phase, 
washed twice, appropriately diluted in fresh medium; and 200 µL were 
administered to each mouse by i.p. injection. Samples of the inoculum were 
plated on Todd-Hewitt broth plates (Difco) supplemented with 0.5% yeast extract 
and 0.5% sheep blood to verify the infectious dose. The plates were incubated 
at 37°C overnight, and the number of colonies was counted next day. 
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Statistics 
Unpaired t-test was applied to natural logarithm values of serum ELISA titres to 
determine the differences between GMT of the immunization groups. Fisher’s 
exact test was used to determine the differences in protection level. Comparison 
was performed between negative control group (adjuvant only) and 
immunization group of interest. 
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